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Abstract
Background The availability of generic topical dermato-
logical drug products is constrained by the limited methods
established to assess topical bioequivalence (BE). A novel
cutaneous pharmacokinetic approach, dermal open-flow
microperfusion (dOFM), can continuously assess the rate
and extent to which a topical drug becomes available in the
dermis, to compare in vivo dermal bioavailability (BA) and
support BE evaluations for topical products.
Objective To evaluate whether dOFM is an accurate,
sensitive, and reproducible in vivo method to characterize
the intradermal BA of acyclovir from 5 % acyclovir
creams, comparing a reference (R) product either to itself
or to a different test (T) product.
Methods In a single-center clinical study, R or T products
were applied to six randomized treatment sites on the skin
of 20 healthy human subjects. Two dOFM probes were
inserted in each treatment site to monitor the intradermal
acyclovir concentration for 36 h. Comparative BA (of R vs.
R and T vs. R) was evaluated based on conventional BE
criteria for pharmacokinetic endpoints (area under the
curve and maximum plasma concentration) where the
90 % confidence interval of the geometric mean ratio
between the T and R falls within 0.80–1.25.
Results The positive control products (R vs. R) were
accurately and reproducibly confirmed to be bioequivalent,
while the negative control products (T vs. R) were sensi-
tively discriminated not to be bioequivalent.
Conclusions dOFM accurately, sensitively, and repro-
ducibly characterized the dermal BA in a manner that can
support BE evaluations for topical acyclovir 5 % creams in
a study with n = 40 (20 subjects in this study).
Key Points
This is the first study showing the utility of clinical
dermal open-flow microperfusion (dOFM) as a
dermal pharmacokinetic approach to compare
dermal bioavailability (BA) and support
bioequivalence (BE) evaluations for a topical
(locally acting) drug product.
dOFM is capable of directly measuring the
penetration of topically applied acyclovir in human
subjects in vivo with low variability for prolonged
durations.
dOFM has the necessary accuracy and
reproducibility to confirm BE for a reference
acyclovir cream 5 % compared with itself, and is
sufficiently sensitive to discriminate inequivalent BA
between two different topical acyclovir cream 5 %
products, in both cases based upon conventional BE
criteria and pharmacokinetic endpoints.
& Frank Sinner
frank.sinner@joanneum.at
1 HEALTH-Institute for Biomedicine and Health Sciences,
Joanneum Research Forschungsgesellschaft mbH,
Neue Stiftingtalstrasse 2, 8010 Graz, Austria
2 Division of Endocrinology and Diabetology, Department of
Internal Medicine, Medical University of Graz, Graz, Austria
3 Division of Therapeutic Performance, Office of Research and
Standards, Office of Generic Drugs, US Food and Drug
Administration, Silver Spring, MD, USA
4 Faculty of Pharmacy, Rhodes University, Grahamstown,
South Africa
5 Present Address: Leslie Dan Faculty of Pharmacy,
University of Toronto, Toronto, ON, Canada
Clin Pharmacokinet (2017) 56:91–98
DOI 10.1007/s40262-016-0442-z
1 Introduction
In many countries, strategies to control healthcare spending
rely upon the availability and use of generic medicines.
The safety and effectiveness of high-quality generic
medicines is ensured through a demonstration of bioe-
quivalence (BE) [1]. The methodology for assessing the BE
of systemically absorbed drugs and for the statistical
assessment of comparative systemic bioavailability (BA)
based upon pharmacokinetic (PK) endpoints is well
established. The same is not true for topical drug products,
which are not intended to be absorbed into the systemic
circulation. In the former instance, conventional regulatory
BE acceptance criteria are based on the maximum plasma
concentration (Cmax) of the drug and the area under the
curve (AUC) of the plasma drug concentration vs. time
profiles. For pharmaceutically equivalent products to be
considered bioequivalent, the 90 % confidence interval for
the ratio of the means of each of these PK endpoints should
fall within specified BE limits (typically 0.80–1.25) on a
log transformed basis [2, 3]. For topical glucocorticoid
drug products, the vasoconstrictor assay is a well-estab-
lished approach to efficiently evaluate BE [4]; however, it
has limited scope only to that class of drug products.
Otherwise, in general, a randomized, double-blind, parallel,
placebo-controlled, comparative, clinical endpoint BE
study that compares the test (generic) product with the
reference listed drug product is the default approach rou-
tinely accepted in USA to demonstrate BE for most locally
or regionally acting topical dosage forms [5]. This impacts
the availability of topical generic products because such
clinical endpoint BE studies may require even more par-
ticipants than the studies originally performed by the
innovator for the new drug [6]. Moreover, clinical endpoint
BE studies may not be the most accurate, sensitive, or
reproducible approach by which to distinguish differences
in BA between different topical drug products [6, 7]. While
a cutaneous PK approach may be a more efficient way to
assess BE, evaluating the rate and extent at which the
topical drug becomes available at the site of action (in the
viable epidermis and dermis) is particularly challenging.
Different recommendations for such BE evaluations have
previously been suggested [8–10].
To address this issue and help make high-quality topical
generic drug products available to patients, Raney et al.
explored the possibility of developing appropriate PK-
based BE approaches for the comparative assessment of
BA from topical dermatological drug products [11]. Evi-
dence supporting the potential feasibility of such alterna-
tive in vivo methods has been presented in the literature,
notably relating to tape stripping [12–14] and dermal
microdialysis [11, 15–21].
More recently, dermal open-flow microperfusion
(dOFM) has been investigated as another potential
approach to assess the BA/BE of topical products. It
facilitates a continuous assessment of the in vivo cutaneous
kinetics of topically administered drugs directly in the
dermis in human subjects. dOFM can assess the intrader-
mal biochemistry and drug concentrations by sampling the
dermal interstitial fluid for up to 48 h (Fig. 1). The benefit
of dOFM has been shown by PK-pharmacodynamic studies
where a wide range of substances from small lipophilic
drugs to large proteins and antibodies could be successfully
monitored in the dermis of healthy human subjects and
patients [22–25]. Additionally, dOFM may be used with
patients experiencing dermatologic diseases and may
enable evaluation of topical BE under conditions where the
disease status of the skin barrier may lead to altered BA of
the drug.
The overall aims of this study were (1) to evaluate
whether dOFM can accurately and reproducibly identify
the in vivo BA of acyclovir in the dermis to be equivalent
between two treatment sites both dosed with the same
R acyclovir cream 5 % (R2 vs. R1) and (2) to evaluate
whether dOFM has the sensitivity to discriminate the
in vivo BA of acyclovir in the dermis as not bioequivalent
(based upon conventional BE criteria) between two treat-
ment sites dosed with compositionally different acyclovir
cream 5 % products (T vs. R1) marketed in different
countries.
2 Materials and Methods
2.1 Healthy Subjects
Twenty healthy human subjects were enrolled (Caucasian,
7 women, 13 men, age 28 ± 5 years).
Fig. 1 Schematic of dermal open flow microperfusion
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2.2 Topical Study Drugs
Acyclovir cream 5 % (Zovirax; Valeant, Bridgewater, NJ,
USA) was used as the R product. Acyclovir cream 5 %
(Aciclovir 1A Pharma—Creme; 1A Pharma GmbH,
Vienna, Austria), which has a different formulation com-
position and from which the topical BA of acyclovir was
observed to be different relative to the R product (unpub-
lished results from exploratory, pilot, in vivo dOFM stud-
ies), was used as the T product.
2.3 dOFM
dOFM probes were inserted intradermally (two probes at
each of the three treatment sites on each limb) and dermal
interstitial fluid samples were continuously collected
(1 lL/min) from a pre-dose baseline time period (-1 h to
0 h) to 36 h post-dose. The dOFM devices (sterile probes,
wearable pumps, accessories; CE certified for human use)
were developed by HEALTH—Joanneum Research GmbH
(Graz, Austria). The devices and their clinical use have
been described in detail previously [23, 24]. In this study,
the newest version of a CE-certified dOFM probe
(DEA15003) was used. Like its precursors, this new dOFM
probe is a highly flexible linear probe with a demarcated
15-mm fully permeable section, and it also has imprinted
position markers to facilitate the precise positioning of the
permeable section of the probe below the treatment area.
The probe’s outer diameter is 0.5 mm and it is inserted
over a length of 30 mm using a standard 0.9-mm (outer
diameter) hollow insertion needle.
2.4 Study Design
After enrollment and qualification of study subjects based
upon the protocol inclusion and exclusion criteria, a set of
three treatment sites (referred to as the ‘test triad’) was
demarcated on each thigh as depicted in Fig. 2 (providing a
total of six treatment sites per subject, each 5.5 cm2).
Twelve dOFM probes were inserted intradermally (two
replicate probes per treatment site) and dermal interstitial
fluid was continuously sampled at 1 lL/min using sterile
perfusate that included 1 % albumin and 600 mg/dL glu-
cose. The skin at a treatment site was cooled using a sterile
ice bag prior to probe insertion as well as during the initial
hour following probe insertion.
At baseline, the transepidermal water loss was measured
on the skin of each leg (Aquaflux AF200; Biox Ltd, Lon-
don, UK) and the baseline serum and dOFM samples were
collected.
At t = 0, 15 mg cream/cm2 of each of the R and
T products were applied to the respective treatment sites on
the skin using a tared spatula. The spreading procedure was
of standardized duration (1 min) for all treatment sites and
care was taken to consistently dose the cream as a
homogenous layer. The R product was applied at two sites
on each thigh (R1 central, R2 non-central) and T non-central
(Fig. 2a) in a randomized order, using treatment random-
ization sequences of either ‘R2–R1–T’ or ‘T–R1–R2’
according to a randomization scheme that had been pre-
defined in the study protocol to rule out the impact of
anatomical location or procedural factors. Treatment sites
were protected by a transparent, non-occlusive, dome-
shaped, perforated plastic shield (Fig. 2b) and samples of
the continuous perfusion from the dOFM probes in the
dermis were collected at 4-h intervals, up to 36 h post-
dose. Glucose in dOFM samples was measured at the
bedside (Super GL; Dr. Mu¨ller Gera¨tebau GmbH, Freital,
Germany) and the relative glucose loss from the perfusate
(relative to 600 mg/dL in %) was calculated to monitor the
exchange rate (‘relative recovery’) across the probe.
Study subjects rested in bed most of the time and slept in
a supine position during the night. The sampling procedure
during the night was identical to that used during the day.
After termination of the study at 36 h, the intradermal
position of each probe was assessed by a longitudinal
ultrasound scan (GE LOGIQ e R6 device with linear
22 MHz probe; GE Healthcare, Vienna, Austria).
To reduce perturbations to the probes and to minimize
variability in the kinetic data, any torsional strains or skin
stretching from anatomical flexion at the test triads across
36 h were minimized through the use of self-adhesive
stabilization rings (HEALTH-Joanneum Research GmbH).
As additional controls to reduce experimental variability
and optimize the precision and reproducibility of the study,
room temperature and relative humidity were tightly con-
trolled throughout the study (22 ± 1 C, 40–60 % relative
humidity).
2.5 Sample Analyses
Acyclovir determination: Samples (20 lL of perfusate plus
D4-deuterated acyclovir internal standard) were processed
by solid-phase extraction (Oasis MCX lElution plate;
Waters, Milford, MA, USA). Samples were washed with
formic acid/water (5 %/95 %, v/v) followed by methanol;
eluted with NH4OH/methanol (5 %/95 %, v/v); evaporated
to dryness; and finally reconstituted in 20 lL methanol/
water (5 %/95 %, v/v). High-performance liquid chro-
matography (HPLC) analysis of acyclovir in dOFM sam-
ples was performed with an Ultimate 3000 HPLC (Thermo
Fisher Scientific, Waltham, MA, USA); ACQUITY-UPLC-
HSS-T3 column (50 9 1.0 mm; Waters) using an isocratic
method and a methanol/water (95 %/5 %, v/v) mobile
phase with a flow rate of 300 lL/min and an injection
volume of 3 lL. Acyclovir detection and quantification
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was performed by mass spectrometry (MS) using a Q-Ex-
active (Thermo) MS/MS in positive heated-electrospray
mode (m/z 226.0935–152.05635 for acyclovir and
230.1196–152.05635 for the acyclovir-D4 internal
standard).
2.6 Pharmacokinetic Data Evaluation
All clinical data were collected with an electronic case
report form (eCRF) within OpenClinica Enterprise Edition.
The eCRF system was hosted by Joanneum Research
GmbH and is 21 CFR Part 11 compliant. All data man-
agement activities were performed and documented
according to international standards and the data manage-
ment plan.
The statistical analysis plan predefined data analysis,
including criteria for the identification and treatment of
possible outliers from intradermal 36-h concentration pro-
files. Possible outliers were identified by a statistical
approach comparing each value with the moving median.
Values that were \50 or [200 % of the moving median
were reanalyzed and the reanalyzed values were used.
Values that were still regarded as outliers according to this
criterion were imputed by the arithmetic mean value of the
preceding and subsequent time point samples, or by using
the carry-last-value-forward approach in situations where
there was no subsequent timepoint, to obtain complete
profiles for PK endpoint calculation. The dermal PK end-
point AUC0–36h was calculated as sum of the dOFM sample
concentrations over 36 h of continuous sampling. The
dermal PK endpoint Cmax was identified as the maximum
concentration during the same duration.
An exploratory pilot study in six subjects where an even
higher topical acyclovir dose was applied over 36 h
showed no detectable acyclovir in the central test sites
when the central test sites were left untreated, and it also
did not show any detectable acyclovir in serum. Therefore,
there was no evidence of any potential for cross-talk
between test sites and all 40 test triads were considered
independent for BE analysis in this proof-of-principle
study.
BE criteria were used to evaluate the dermal PK end-
points for the positive control for BE (R2 vs. R1) and the
negative control for BE (T vs. R1) based on the typical
acceptance criteria for BE. The dermal PK endpoints
AUC0–36h and Cmax were log transformed prior to analysis.
The results were evaluated to determine whether the 90 %
confidence interval of the mean ratios of T/R fell within the
conventional BE limits of 0.80–1.25.
3 Results
3.1 dOFM Data Acquisition
All subjects tolerated the 36-h continuous dOFM sampling
and no dropouts or serious adverse events occurred. No
adverse event (or serious adverse event) related to the
dOFM technique occurred during the study. Dermal sam-
pling and the probe perfusion equilibrium were stable for
36 h, verified by stable glucose exchange rates (of
approximately 60 %) across the probes. Applying the cri-
terion for possible outliers within acyclovir profiles yielded
a sample reanalysis rate of 3 %. After reanalysis, the rate of
possible outliers was reduced to 1 % of all samples. All the
acyclovir profiles (36 h each) of the 240 dOFM probes in
the pivotal study (six probes per thigh on each of two
thighs on each of 20 subjects) were included in the statis-
tical evaluation. A characteristic steady decline in the later
phase of the PK profile after Cmax, which is usually seen in
systemic blood concentration PK studies, when the rate of
drug clearance from the systemic circulation dominates
over the rate of drug input into the systemic circulation
(e.g., from an oral dose), was not clearly observed for
acyclovir in the dermis after topical administration in this
study, even across 36 h of sampling (Fig. 3).
Fig. 2 Scheme (a) and
photograph (b) of the duplicate
test triad for comparative
bioavailability assessment. Two
treatment sites per test triad
were dosed with the reference
product (R1: central, R2: non-
central) and one treatment site
was dosed with the test product
(T)
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3.2 Comparative BA
The statistical comparison of PK endpoints using BE cri-
teria are summarized in Table 1. The mean (and geometric
mean) results across treatment groups for each PK endpoint
are provided in Table 2.
BE was confirmed for the positive control products (R2
vs. R1) for AUC0–36h (0.86–1.18) and Cmax (0.86–1.21). An
exploratory statistical re-sampling procedure showed that
n = 36 (18 subjects in this study design) would have been
sufficient to demonstrate BE for R2 vs. R1 based on
AUC0–36h and n = 38 (19 subjects in this study design)
would have been sufficient based on Cmax.
The negative control products (T vs. R1) failed to
demonstrate BE for both parameters, AUC0–36h (0.69–1.05)
and Cmax (0.61–1.02).
Consistent probe depths were confirmed for the R treat-
ment sites (R1: 0.83 ± 0.20 mm, R2: 0.81 ± 0.22 mm,
p = 0.5329). The mean probe depth (T: 0.73 ± 0.18 mm,
p = 0.0007) was lower in the T treatment sites than it was
in either R site, but a regression analysis indicated that
there was no significant impact of probe depth on the AUC
for acyclovir (p = 0.1001).
4 Discussion
This in vivo study illustrates the feasibility of dOFM to
compare dermal PK and to assess BA of acyclovir from
T and R topical creams in situ in the dermis. The results
demonstrate that dOFM accurately and reproducibly
determined the positive control products to be BE (R2 vs.
R1) and that it had the sensitivity to differentiate the neg-
ative control products (T vs. R1) as not being BE, in both
cases based upon PK endpoints and the usual BE accep-
tance criteria.
The dOFM probes facilitated a stable intradermal sam-
pling for 36 h from 4 R and 2 T treatment sites simulta-
neously in each subject, and thereby enabled
characterization of the dermal PK profile for a relatively
slow and low level of permeation of topical acyclovir. All
subjects tolerated 36-h post-dose sampling well and no
subject withdrew from the study prematurely. The positive
subject compliance may be, in part, attributed to the
compact wearable open-flow microperfusion devices,
allowing enhanced mobility of the subjects. Bedside glu-
cose analysis in dermal samples showed that exchange
across the dOFM probe (the ‘relative recovery’) was
stable over 36 h and thus indicated that skin cooling and
the maintenance of an equilibrium period of 60 min post
insertion was appropriate for this study.
dOFM delivered stable acyclovir profiles (\1 % out-
liers) and thereby demonstrated good reliability. Impor-
tantly, the high precision and reproducibility of the study
results are attributable to several specific controls imple-
mented to standardize and optimize study procedures, such
as stabilization of the treatment sites to reduce strain and
stretching, pain management during probe insertion to
improve consistency and control of probe depth insertion,
cooling after implementation to reduce trauma formation,
and control of ambient temperature and humidity. Fur-
thermore, several factors that were not necessarily amen-
able to better control, but which had a potential to influence
the variability, were monitored so that their influence on
variability could be evaluated and potentially corrected for:
transepidermal water loss and impedance were monitored
to evaluate potential subgroups in the population with skin
permeability that may be more or less discriminating to
differences in topical BA; glucose and deuterated water
were monitored in the perfusate to identify any perturba-
tion in the sampling environment; probe depth of the entire
perfusate exchange area and flow rates of each time
interval of each probe were monitored. The PK endpoint
data in this study were not corrected by any of those
factors.
Acyclovir products were chosen for this proof-of-prin-
ciple dOFM study of comparative BA owing to the avail-
ability of 5 % cream products with different compositions
and potentially different BA, and also because a dermal PK
approach may have particular value to assess BE of topical
products intended for local action rather than a clinical
endpoint study in patients. The hydrophilicity of this drug,
however, is not representative of most topical drugs and
further research with hydrophobic drugs is warranted. The
Cmax was not seen for the reference product within 36 h,
Fig. 3 Dermal open flow microperfusion (dOFM) acyclovir concen-
tration profiles for the test product (T) site and the two reference (R1
and R2) sites (mean ± standard error of the mean, n = 40 test triads
in 20 subjects). Acyclovir was analyzed from one pre-dose sample
(spanning -1 to 0 h) and nine pooled post-dose samples (spanning
0–4, 4–8 … 32–36 h). The post-dose concentrations are plotted at the
mid-point of the time intervals (2, 6 … 34 h)
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and the slow and ongoing permeation of acyclovir from
both 5 % cream products produced a PK profile from
which it was not possible to calculate the AUC0–?.
Hydrophilic drugs such as acyclovir may be poorly
absorbed owing to a low partitioning through the skin’s
hydrophobic permeability barrier, the stratum corneum
[26]. Low levels of percutaneous absorption and slow
kinetics are among the reasons why prior studies using
conventional dermal microdialysis, which were limited to a
5-h post-dose sampling duration, only succeeded to sample
acyclovir when simultaneously inhibiting local skin blood
flow [26, 27].
This study was intended to evaluate how accurately,
precisely, and reproducibly dOFM could monitor the rate
and extent to which a topically applied drug (acyclovir)
becomes available in the dermis, and to compare the
dermal BA of acyclovir between T and R creams
administered using the same clinically relevant dose
amount under essentially identical study conditions, using
a single-dose study design. The labeled use of these
acyclovir cream products involves a repeated dosing
regimen throughout each day of use. Repeated dosing
(e.g., every 4–5 h) is an effective strategy to maintain
therapeutic drug concentrations at the site of action.
However, differences in BA that might not be evident in a
study where the products were re-dosed every 4 h may
become evident in clinical use, where the product may
not be re-dosed precisely every 4 h, particularly if one
product dries more rapidly. In addition, a multiple dosing
study design could obscure or convolute PK endpoints
such as Cmax, which were of interest to compare. There-
fore, a single-dose study design was considered to be the
most appropriate for the purposes of comparing acyclovir
BA between the T and R products precisely because it
may be more sensitive and discriminating than a multiple
dosing study design. Indeed, it is possible that the dif-
ferences in BA observed between the T and R products in
this study may not be distinguishable in the clinical use of
these products.
The application of dOFM accurately and reproducibly
confirmed BE when acyclovir cream 5 % (Zovirax) was
compared with itself (R2 vs. R1). The statistical power
estimation revealed that the sample size of n = 40 (20
subjects in this study) was well chosen, as n = 38 (19
subjects) would have been sufficient to demonstrate BE
with a confidence level above 80 %. Both PK endpoints for
the T vs. R product comparison failed to satisfy the con-
ventional criteria for BE, demonstrating that dOFM was
sufficiently sensitive to discriminate between the T and
R products.
5 Conclusion
In this study, dOFM showed low variability and high
robustness, successfully characterizing the dermal BA of
acyclovir from T and R products in a manner that could
support evaluations of BE for topical acyclovir cream 5 %
Table 1 Statistical evaluation comparing PK endpoints using typical BE criteria (n = 40 test triads in 20 subjects)
Comparison PK endpoint 90 % confidence interval T/R (point estimate) Outcome
R2 vs. R1 AUC0–36 h 0.86–1.18 1.01 Positive BE result Confirmed
R2 is considered BE to R1Cmax 0.86–1.21 1.02
T vs. R1 AUC0–36 h 0.69–1.05 0.85 Negative BE result Confirmed
T is not considered BE to R1Cmax 0.61–1.02 0.79
AUC area under the curve, BE bioequivalence, Cmax maximum plasma concentration, PK pharmacokinetic, R reference, T test product
Table 2 Pharmacokinetic
endpoints AUC0–36 h and Cmax
Product AUC0–36 h (ng h/mL) Cmax (ng/mL)
Mean ± SEMa Geometric mean ± SEMb Mean ± SEM Geometric mean ± SEM
R1 26.75 ± 3.85 16.23 ± 1.19 1.32 ± 0.18 0.85 ± 1.18
R2 26.32 ± 4.07 16.34 ± 1.18 1.29 ± 0.17 0.86 ± 1.17
T 25.38 ± 4.52 13.84 ± 1.20 1.12 ± 0.19 0.67 ± 1.19
AUC area under the curve, Cmax maximum plasma concentration, R reference SEM standard error of the
mean, T test product
a Mean refers to the arithmetic mean and corresponds to the arithmetic mean profiles in Fig. 2
b Geometric mean refers to the geometric mean that was used in the statistical evaluation reported in
Table 1
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products in vivo with n = 40 (20 subjects in the indepen-
dent replicate leg design used for this study). Factors
contributing to variability of in vivo dermal PK data were
well controlled in this clinical study, which is the first to
evaluate clinical dOFM for comparative dermal BA/BE
assessment.
The results of this study suggest that an appropriately
designed and well-controlled in vivo dOFM study could
have the requisite accuracy, precision, reproducibility, and
statistical power to compare the rate and extent to which a
topically applied drug such as acyclovir becomes available
in the dermis and that dOFM may provide a viable dermal
PK approach for the BE assessment of topical drug
products.
In the future, the sensitivity of dOFM may be even
further improved for compounds permeating the skin more
rapidly and to a greater extent than acyclovir, by refine-
ments in subject inclusion/exclusion criteria, by correcting
for perturbations to the dermal sampling caused by changes
in blood flow or variations in probe depth, or by choosing
shorter dose durations and monitoring the dermal PK for
the T and R products during the period when the drug is
being cleared from the skin. Further research exploring
dOFM and other cutaneous PK methodologies to evaluate
topical BA/BE is warranted based upon the results of this
study.
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